Delivering regenerative solutions

Tissue Regenix is a company that focuses on delivering practical solutions to real clinical issues using its patented dCELL® process.

Company News

Products

The dCELL® Technology comprises a patented process which removes cells and other components from animal and human tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Products

  • Vascular Patch

    The dCELL® Vascular Patch provides a highly biocompatible patch for peripheral vascular reconstruction that supports infiltration of the patient’s own cells allowing host tissue regeneration. The dCELL® Vascular Patch is manufactured from porcine pericardium using the proprietary dCELL® process. The dCELL® process removes cellular material from tissues while maintaining the structural and biomechanical properties. This results in an acellular, immunocompatible and immediately functional material.…more

Who Are Tissue Regenix?

Delivering regenerative solutions
Tissue Regenix is a company that focuses on delivering practical solutions to real clinical issues using its patented dCELL® process.

  • Our technology is already in use clinically and there is a pipeline of products to address significant medical market opportunities.
  • Our products don’t require special storage and are designed so surgeons can use existing operating techniques.
  • The dCELL® Process removes foreign cells & DNA and provides a matrix that repopulates with patients own cells once its implanted - integrating into the patients own tissues
  • Regenerative medical products made from animal tissue could provide long term answers to problems unlike man-made/processed biomaterials.

dCELL® Evidence

Academic Papers The dCELL® Process has a substantial database of peer reviewed papers and presentations that is continuing to grow. Tissue Regenix will continue to build on this platform as products are launched.

Read More